What is the recommended treatment and dosing for non‑purulent cellulitis in an otherwise healthy adult?

Treatment for Adult Nonpurulent Cellulitis

For otherwise healthy adults with nonpurulent cellulitis, treat with a beta-lactam antibiotic targeting beta-hemolytic streptococci for 5 days, using oral cephalexin 500 mg four times daily or penicillin VK 500 mg four times daily as first-line options. 1, 2

Primary Antibiotic Selection

The IDSA guidelines consistently emphasize that nonpurulent cellulitis (no purulent drainage, exudate, or abscess) is primarily caused by beta-hemolytic streptococci, not MRSA 1, 3. Therefore:

First-line oral options:

• Cephalexin 500 mg four times daily (most commonly used) 4, 2
• Penicillin VK 500 mg four times daily 2
• Amoxicillin 500 mg three times daily (alternative beta-lactam)

For hospitalized patients with nonpurulent cellulitis:

• Cefazolin 1 g IV every 8 hours 1, 4, 2
• For patients ≥120 kg, consider cefazolin 3 g every 8 hours based on emerging evidence 5

Duration of Therapy

Treat for 5 days 2. The 2014 IDSA update provides strong evidence (high quality) that 5 days is sufficient, with extension only if infection has not improved within this timeframe 2. This is a significant departure from the older 2011 guidelines that recommended 5-10 days 1.

When to Add MRSA Coverage

Do NOT routinely cover MRSA for nonpurulent cellulitis 1, 6. Add MRSA coverage only if:

• Patient fails to respond to beta-lactam therapy after 48-72 hours 1
• Signs of systemic toxicity are present 1
• Specific risk factors exist: penetrating trauma, evidence of MRSA elsewhere, nasal MRSA colonization, injection drug use, or SIRS 2

If MRSA coverage is needed, add:

• TMP-SMX 1-2 double-strength tablets twice daily PLUS continue beta-lactam 1
• OR switch to clindamycin 300-450 mg three times daily (covers both streptococci and MRSA) 1

Dosing Considerations

Recent evidence suggests weight-based dosing may improve outcomes. For clindamycin or TMP-SMX, inadequate dosing (<10 mg/kg/day for clindamycin or <5 mg TMP/kg/day for TMP-SMX) is independently associated with clinical failure 7. However, standard fixed dosing remains guideline-recommended for most patients.

Outpatient vs Inpatient Management

Treat as outpatient if: No SIRS, normal mental status, hemodynamically stable 2

Hospitalize if: SIRS present, altered mental status, hemodynamic instability, concern for deeper/necrotizing infection, severe immunocompromise, or outpatient treatment failure 2

Adjunctive Measures

• Elevate the affected extremity 2
• Examine interdigital toe spaces and treat any tinea pedis, as fissuring/maceration can serve as portal of entry 2
• Consider systemic corticosteroids (prednisone 40 mg daily for 7 days) in nondiabetic adults, though evidence is limited 2, 8

Common Pitfalls

1. Overuse of MRSA coverage: The role of CA-MRSA in nonpurulent cellulitis remains unknown, and empiric coverage is unnecessary in most cases 1
2. Treating bilateral lower extremity "cellulitis": This is rarely true cellulitis—consider venous stasis dermatitis, contact dermatitis, or other mimickers 9, 6
3. Excessive treatment duration: 5 days is sufficient; longer courses increase adverse effects without improving outcomes 2
4. Obtaining cultures: Blood cultures and tissue aspirates are not routinely recommended for typical cellulitis 2